Information needs for medication coverage decisions in a state Medicaid program

Medical Care

Volumn 37, Issue 4 SUPPL. 1, 1999, Pages

  Croghan, Thomas W ^a,b   Johnstone, Bryan M ^a,b   Buesching, Don P ^a,b   Kessler, Ronald C ^c  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antipsychotics; Medi Cal; Mental illness; Selective serotonin reuptake inhibitors; Tricyclic antidepressants

Indexed keywords

NEUROLEPTIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; CLASSIFICATION; COMORBIDITY; COST CONTROL; DECISION MAKING; DRUG APPROVAL; ECONOMICS; HEALTH CARE PLANNING; HEALTH INSURANCE; HUMAN; INFORMATION PROCESSING; INSURANCE; MEDICAID; MENTAL DISEASE; METHODOLOGY; ORGANIZATION AND MANAGEMENT; OUTCOME ASSESSMENT; PREVALENCE; UNITED STATES;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; CALIFORNIA; COMORBIDITY; COST CONTROL; DATA COLLECTION; DECISION MAKING; DRUG APPROVAL; HUMANS; INSURANCE COVERAGE; INSURANCE, PHARMACEUTICAL SERVICES; MEDICAID; MENTAL DISORDERS; OUTCOME ASSESSMENT (HEALTH CARE); PREVALENCE; STATE HEALTH PLANS; TECHNOLOGY ASSESSMENT, BIOMEDICAL; UNITED STATES;

EID: 0033112123     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005650-199904001-00005     Document Type: Article

References (29)

1. AHCPR Depression Guideline Panel. Depression in primary care, vol 2: Treatment of major depression. Clinical Practice Guideline Number 5. Rockville, MD: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. AHCPR Publication No. 93-0550, 1993.
2. Potter WZ, Rudorfer MV, Monji H. The pharmacologic treatment of depression. N Engl J Med 1991;325:633.
3. Rudorfer MV, Manji HK, Potter WZ. Comparative tolerability profiles of the newer versus older antidepressants. Drug Safety 1994;10:1846.
4. McCombs JS, Nichol MB, Stimmel GL, Sclar DA, Beasley CM, Gross LS. The cost of antidepressant drug therapy failure: A study of antidepressant use patterns in a Medicaid population. J Clin Psychiatry 1990;51(suppl 6):6069.
5. Katon W, VonKorff M, Lin E, Bush T, Ormel J. Adequacy and duration of antidepressant treatment in primary care. Med Care 1992;30:67.
6. Simon G, VonKorff M, Wagner EH, Barlow W. Patterns of antidepressant use in community practice. Gen Hosp Psychiatry 1993;15:399.
7. Mintz J, Mintz LI, Arruda MJ, Hwang SS. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 1992;49:761.
8. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:9.
9. WHO Composite International Diagnostic Interview, version 1.0. Geneva: World Health Organization, 1990.
10. Wittchen HU, Essau CA, Von Zerssen D, Krieg JC, Zaudig M. Lifetime and six-month prevalence of mental disorders in the Munich Follow-up Study. Eur Arch Psychiatry Clin Neurosci 1992;241:247.
11. Hotopf M, Lewis G, Normand C. Are SSRIs a cost-effective alternative to tricyclics? Br J Psychiatry 1996;168:404.
12. Montgomery SA, Henry J, MacDonald G, Dinan T, Lader M, Hindmark I, et al. Selective serotonin reuptake inhibitors: A meta-analysis of discontinuation rates. Int Clin Pharmacol 1994;9:47.
13. Song F, Freemantle N, Sheldon TA, House A, Mason J. Selective serotonin reuptake inhibitors: Meta-analysis of efficacy and acceptability. BMJ 1993;306:683.
14. Cocks DL, Croghan TW. The economic organization of health resource allocation: Decision making in the new environment. Am J Managed Care 1996;2:1035.
15. Woods SS, Rizzo JA. Cost-effectiveness of antidepressant treatment reassessed. Br J Psychiatry 1997;170:257.
16. Simon GE, VonKorff M, Heiligenstein JH, Revicki DA, Grothaus L, Katon W, et al. Initial antidepressant choice in primary care: Economic outcomes in a health maintenance organization. JAMA 1996;275:1897.
17. Sclar DA, Robison LM, Skaer TL, Leggs RS, Nemee NL, Galin RS, et al. Antidepressant pharmacotherapy: Economic outcomes in a health maintenance organization. Clin Ther 1994;16:715.
18. Skaer TL, Sclar DA, Robison LM, Galin RS, Legg RF, Nemic NL. Economic evaluation of amitriptyline, desipramine, nortriptyline, and sertraline in the management of patients with depression. Curr Ther Res 1994;56:556.
19. Croghan TW, Lair TJ, Engelhart L, Crown WE, Copley-Merriman C, Melfi CA, et al. Effect of antidepressant therapy of health care utilization and costs in primary care. Psychiatric Services 1997;48:1420.
20. Crown WE, Obenchain RL, Engelhart L, Lair TJ, Buesching DP, Croghan TW, et al. The application of sample selection models to outcomes research: The case of evaluating the effects of antidepressant therapy on resource utilization. Stat Med 1998;17:1943.
21. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789.
22. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective, and schizophreniform disorders: Results of an international collaborative trial. Am J Psychiatry 1997;154:457.
23. Beasley CM, Tollefson GD, Tran PV, Satterle W, Sanger T, Hamilton S, and the Olanzapine HGAD Study Group. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996:14:111.
24. Chouinard G, Jones B, Remington G, Bloom D, Addington D, Mac Ewan GW, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25. [Erratum, J Clin Psychopharmacol 1993;13:149.]
25. Rice DP, Miller LS. The economic burden of schizophrenia: conceptual and methodological issues, and cost estimates. In: Moscarelli M, Rupp A, Sartorius N, eds. Handbook of mental health economics and health policy, vol 1. New York: John Wiley and Sons, 1996:321.
26. Norquist GS, Wells K. Mental health needs of the uninsured. Arch Gen Psychiatry 1991;48:475.
27. Johnstone BM, Croghan TW, Kessler RC, Lehman AF, Kendler KS, Abelson JS, et al. Health insurance status and service utilization in a community sample of persons with non-affective psychosis: The National Comorbidity Survey. Psychiatric Serv; in press.
28. Obenchain RL, Johnstone BM. Mixed-model imputation of cost data for early discontinuers from a randomized clinical trial. Drug Information Journal 1999;33:1.
29. Lanier D, Clancy C. Primary care research: Current challenges, future needs. J Fam Pract 1997;44:434.